Eton Pharmaceuticals, Inc. (ETON)
NASDAQ: ETON · IEX Real-Time Price · USD
3.500
+0.080 (2.34%)
At close: Jul 19, 2024, 4:00 PM
3.560
+0.060 (1.71%)
Pre-market: Jul 22, 2024, 7:00 AM EDT

Company Description

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases.

The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals logo
Country United States
Founded 2017
IPO Date Nov 13, 2018
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 30
CEO Sean E. Brynjelsen

Contact Details

Address:
21925 W. Field Parkway, Suite 235
Deer Park, Illinois 60010-7278
United States
Phone (847) 787-7361
Website etonpharma.com

Stock Details

Ticker Symbol ETON
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001710340
CUSIP Number 29772L108
ISIN Number US29772L1089
Employer ID 37-1858472
SIC Code 2834

Key Executives

Name Position
Sean E. Brynjelsen President, Chief Executive Officer and Director
James R. Gruber CPA Chief Financial Officer, Treasurer and Secretary
David C. Krempa Chief Business Officer
Ingrid Hoos Senior Vice President of Regulatory Affairs
Kevin Guthrie Executive Vice President of Commercial Operations

Latest SEC Filings

Date Type Title
Jul 15, 2024 8-K Current Report
Jun 21, 2024 8-K Current Report
Jun 11, 2024 8-K Current Report
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
Apr 30, 2024 8-K Current Report
Apr 30, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Apr 26, 2024 DEF 14A Other definitive proxy statements
Apr 18, 2024 8-K Current Report
Mar 26, 2024 S-8 Securities to be offered to employees in employee benefit plans